OBN: Supporting Emerging Life Sciences Companies

OBN is the Membership organisation supporting and bringing together the UK’s emerging life sciences companies, corporate partners and investors. Our 360-plus Member companies are located across the Golden Triangle and beyond to Nottingham, Manchester and Scotland benefiting from our networking, partnering, purchasing, advising and advocacy activities.

Next OBN Event slim light  green centre
ID_black_horizontal

BioTrinity 2015: Europe’s Leading European Biopartnering and Investment Conference – London

Monday 11 May – Wednesday 13 May 2015

A world-class conference providing the best opportunity to meet investors, senior licensing executives from global pharma organisations and senior management of innovative drug development and platform technology companies, diagnostics and medical technology companies.

* Network with over 1,000 delegates from 34 countries including 130 investor delegates
* Gain insight into securing investment from the smartest money in global life sciences
* Be inspired by pharma’s hottest dealmakers offering fresh perspectives
* Take your pick of over 100 of Europe’s best R&D company showcases
* Select who you want to meet in one-to-one meetings through partneringONE®

To go to the dedicated website please click here.

Next OBN Event slim light  green
OBN_ID_RGB

OBN PharmaTuesday: ‘Should Pharma Externalisation go to 100%?’ – Cambridge

Tuesday 14 April 2015

Should Pharma Externalization go to 100%?

At this excellent upcoming PharmaTuesday, senior speakers from all sides of the industry will debate the contentious question whether biotech really can afford for big pharma to externalise R&D completely? Expect vigorous debate.

 

Key questions to be explored:

* How far should pharma externalization go?
* Will it hinder emerging companies if development expertise is lost from very large companies?
* What will be the economic effect of further externalization on the R&D and CRO sector?
* Will pharma sponsored innovation hubs be a substitute for pharma R&D organisations?
* At what point, if any, could further externalisation harm the ecosystem whose growth it has driven?

To register, please click here.

Read more
OUR PATRONS & SPONSORS
OUR SUPPORTERS
LATEST NEWS
01
April
OBN Extends Agreement with Fisher Scientific
Wednesday, April 1st, 2015
  OBN is delighted to announce that it has signed a new agreement awarding Fisher Scientific it ... Read More »
30
March
The Strength & Opportunity 2014 Report is now available
Monday, March 30th, 2015
We are pleased to let you know that the Strength & Opportunity 2014 Report is now available prov ... Read More »
30
March
Clinicians, Researchers and Industry collaborate with the 100,000 Genomes Project
Monday, March 30th, 2015
March 26, 2015: First 10 companies come forward to create the GENE Consortium, to accelerate the dev ... Read More »
LATEST JOBS
30
March
Interim Head of Commercial Planning
Monday, March 30th, 2015
Our client, based in the UK, is a well-funded, small speciality pharma company currently at a very e ... Read More »
18
March
REF: 882240 Interim Medical Director EMEA
Wednesday, March 18th, 2015
Our client is seeking an experienced interim Medical Affairs professional to support their growing M ... Read More »
13
March
Senior Statistician
Friday, March 13th, 2015
S-cubed Biometrics is a dynamic and successful biometrics and statistical consultancy company in the ... Read More »